A RANDOMIZED, OPEN-treatment, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 compared with TAMOXIFEN FOR women WITH OVARIAN CANCER, that blood tests suggest is returning after COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY To determine efficacy based on PFS of INCB024360 versus tamoxifen among subjects with CA-125 elevation following complete remission with first-line chemotherapy for advanced disease by investigator.

• Country None
• organs None
• Specialty None

A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Response to Any Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy including Biologics The Primary Objectives of this study are to determine the: • Safety and tolerability of 3 months of dosing of INCB028050 in patients with active rheumatoid arthritis who have had inadequate response t...

• Country None
• organs None
• Specialty None

A Phase 2 Study of INCB039110 in combination with docetaxel in advanced Non–Small Cell Lung Cancer Safety Run-In Phase (Part 1): • To evaluate the safety and tolerability of INCB039110 in combination with docetaxel and select their doses for further evaluation. Randomized Phase (Part 2): • To ev...

• Country None
• organs None
• Specialty None

A Phase 2 Study of Ruxolitinib in Combination With Pemetrexed/Cisplatin and for Treatment of Subjects With Advanced Lung Cancer Estudio Fase IIde Ruxolitinib en combinación con Pemetrexed/Cisplatino y Pemetrexed para el tratamiento de pacientes con cáncer de pulmón avanzado ?Part 1: To evaluate the safety and tolerability of ruxolitinib in combination with pemetrexed/cisplatin and select a dose for further evaluation ?Part 2: To evaluate and compare the OS of subjects ...

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in patients with Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations Phase 1 (Safety Run-in Phase): • To evaluate the safety and tolerability of INCB039110 in combination with erlotinib and select a dose for further evaluation. Phase 2 (Randomized Phase): • To evalu...

• Country None
• organs None
• Specialty None

A Study of Ruxolitinib in Combination With Regorafenib in Subjects Metastatic Colorectal Cancer Estudio de Ruxolitinib combinado con Regorafenib en pacientes con Cancer Colorectal Metastasico Part 1 (Safety Run-in) - To determine the doses of ruxolitinib and regorafenib that are safe and tolerable when administered in combination. Part 2 (Randomized Phase) - To evaluate and compare the OS...

• Country None
• organs None
• Specialty None

Estudio controlado de mielofibrosis con tratamiento oral con inhibidor de JAK (Estudio COMFORT-II) COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment-II Comparar la eficacia, la seguridad y la tolerabilidad de INCB018424 dos veces al día con las del mejor tratamiento disponible en pacientes con mielofibrosis primaria (MFP), mielofibrosis tras policite...

• Country None
• organs None
• Specialty None

A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of INCB018424 in patients with advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea To evaluate the safety and efficacy profile of three different treatment regimens of INCB018424 administered to two groups of patients; those with polycythemia vera (PV) and those with essential th...

• Country None
• organs None
• Specialty None

Phase 3 Study of Epacadostat and Pembrolizumab in Melanoma To compare the progression-free survival (PFS) of the combination of pembrolizumab and epacadostat versus pembrolizumab and placebo (i.e. 2 treatment groups) based on RECIST 1.1 by independent central...

• Country None
• organs None
• Specialty None

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement The primary objective of this study is to evaluate the efficacy of INCB054828 in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

• Country None
• organs None
• Specialty None